Evaluating the implementation of the 20-valent pneumococcal conjugate vaccine for paediatric immunization in Australia
This cost-effectiveness analysis estimated that adoption of PCV20 into the Australian paediatric NIP would be dominant versus PCV13 and PCV15, leading to health benefits and cost-savings.
Authors
- Sophie Warren
- Aleksandar Ilić (ORCID: https://orcid.org/0000-0002-8594-3539)
- Valda Anne Struwig
- An Ta (ORCID: https://orcid.org/0000-0003-0929-6365)
- Amit Vilas Thorat
Institutions
- Pfizer (United Kingdom) (GB)
- Pfizer (Australia) (AU)
- University of Portland (US)
- Cytel (United States) (US)
Publication Details
- Journal
- Vaccine
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1016/j.vaccine.2025.127996
- Citations
- 1
- Primary Topic
- Pneumonia and Respiratory Infections
- Type
- article
- Field-Weighted Citation Impact
- 1.35